![Boston_H_color[33632]_edited.png](https://static.wixstatic.com/media/e60c5c_0b72738a80554196840094a8e387c5ed~mv2.png/v1/fill/w_338,h_77,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/Boston_H_color%5B33632%5D_edited.png)
Frontline Treatment of CD30-Expressing Lymphomas
Tue, Aug 06
|Seasons 52
Seattle Genetics cordially invites you to an educational program. Frontline Advancements: Clinical Data Overview of Echelon-1 and Echelon-2.
Time & Location
Aug 06, 2019, 6:00 PM
Seasons 52, 220 Boylston St, Chestnut Hill, MA 02467, USA
Guests
About The Event
To RSVP or for information regarding ADCETRIS, contact your local Seattle Genetics Account Manager, Carrie Maricic at (603) 339-3451 or via email at cmaricic@seagen.com.
FRONTLINE ADVANCEMENTS:
CLINICAL DATA OVERVIEW OF ECHELON-1 AND ECHELON-2
Join us to review data from 2 pivotal trials assessing ADCETRIS+AVD vs ABVD in previously untreated Stage III/IV classical Hodgkin lymphoma (cHL), and ADCETRIS+CHP vs CHOP in previously untreated CD30-expressing peripheral T-cell lymphomas (PTCL).1
Presented by Krista Tucker, APRN
Tufts University Medical School
Healthcare professionals including hematologist oncologists, medical oncologists, pharmacists, PAs, NPs, and RNs
are encouraged to participate in this valuable dialogue.